Oxadiazole derivative as DGAT inhibitors
US7795283B2 · kind B2 · utility
7Cited by
6References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 2005 |
| Grant date | Sep 14, 2010 |
| Priority date | — |
| Expiry date | Dec 9, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.